ClinicalTrials.gg
TerminatedNCT06527404Updated Jul 27, 2026

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

A Phase 3 interventional study of Rocatinlimab and Placebo in Prurigo Nodularis, sponsored by Amgen. Terminated at 192 sites in 30 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
469
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.

Enrollment
2nd of 21
469 · median 140
Started
2024
with 6 others
Phase 3
10 of 23
1 open now
Registered
19th of 23
by date
Lead sponsor
1 of 23
Amgen

Among the 23 studies in Prurigo with a site in United States, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2024, is one of 10 in phase 3, and was the 19th registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prurigo with a site in United States, or all of them as a file.
02

Study summary

The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).

03

Conditions studied

  • Prurigo Nodularis

Browse trials for

Keywords

  • Rocatinlimab
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years (or any legal adult age within the country if it is older than 18 years)
  • Clinical Diagnosis of Prurigo Nodularis that has been present for at least 3 months.
  • Patient-reported average Daily Itch Score based on electronic daily diary assessment the last 7 days prior to and including day 1.
  • Has ≥ 20 prurigo nodularis nodules in total with bilateral distribution on both legs and /or arms and /or trunk.
  • History of inadequate response to topical therapies of medium or higher potency or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks).

Exclusion criteria

Exclusion Criteria:

  • Skin or systemic morbidities, other than prurigo nodularis, that have been active within the last 3 months that interfere with assessment of study outcomes including but not limited to atopic dermatitis (signs or symptoms other than dry skin or requiring treatment is not allowed; use of emollients and/or history of AD is allowed).
  • Prurigo nodularis secondary to medications.
  • Prurigo nodularis secondary to neurologic or psychiatric medical conditions.
  • Treatment with any systemic biologic or systemic biologic immunomodulatory therapy for prurigo nodularis or any other , inflammatory, or allergic disease within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 prerandomization.
  • Treatment with live virus including 12 weeks prior to day 1 prerandomization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
469 participants (actual)

Study arms

  • Experimental
    Arm A: Blinded Treatment

    Participants will receive rocatinlimab dose 1 subcutaneously (SC) during Treatment Period A and B.

    Drug: Rocatinlimab

  • Experimental
    Arm B: Blinded Treatment

    Participants will receive rocatinlimab dose 2 SC during Treatment Period A and B.

    Drug: Rocatinlimab

  • Experimental
    Arm C: Blinded Treatment

    Participants will receive matching placebo SC during Treatment Period A and B.

    Drug: Placebo

  • Experimental
    Arm D: Open-label

    Participants will receive open-label rocatinlimab dose 1 SC during Treatment Period B.

    Drug: Rocatinlimab

Interventions

06

What researchers measure

Primary outcomes

  1. Global: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Week 24

    Time frame: Up to 24 weeks

  2. US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 24

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Global: Number of Participants Achieving Improvement in Prurigo Nodularis Stage Assessment Score at Week 24

    Time frame: Week 24

  2. Global: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 24

    Time frame: Baseline and Week 24

  3. Global: Percentage Improvement from Baseline in Weekly Average of Daily Itch Score at Week 24

    Time frame: Baseline and Week 24

  4. Global: Number of Participants Achieving Reduction in Weekly Average Daily Prurigo Nodularis Skin Pain Assessment at Week 24 in Those with Baseline NRS Above Cutoff

    Time frame: Baseline and Week 24

  5. US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Week 24

    Time frame: Baseline and Week 24

  6. US Only: Number of Participants with Improvement in Prurigo Nodularis Stage Assessment at Week 24

    Time frame: Week 24

  7. US Only: Percent Improvement from Baseline in Weekly Average of Daily Itch Score at Week 24

    Time frame: Week 24

  8. US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Skin Pain Assessment at Week 24 in Participants With Baseline Score Greater Than or Equal to a Cutoff Score

    Time frame: Week 24

  9. Change from Baseline in Weekly Average of Daily Itch Score at Weeks 24, 36 and 52

    Time frame: Baseline, Week 24, Week 36 and Week 52

  10. Percent Improvement from Baseline in Weekly Average of Daily Itch Score at Week 36 and 52

    Time frame: Baseline, Week 36 and Week 52

  11. Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Weeks 16, 36 and 52

    Time frame: Baseline, Week 16, Week 36 and Week 52

  12. Number of Participants Achieving Weekly Average of Daily Itch Score Less than a Cutoff Score at Week 36 and 52

    Time frame: Week 36 and Week 52

  13. Change from Baseline in Prurigo Nodularis Stage Assessment Score at Week 24, 36, and 52

    Time frame: Baseline, Week 24, Week 36 and Week 52

  14. Number of Participants Achieving Improvement in Prurigo Nodularis Stage Assessment Score at Weeks 36 and 52

    Time frame: Week 36 and Week 52

  15. Number of Participants Achieving Improvement in Prurigo Nodularis Activity Assessment Score at Weeks 24, 36 and 52

    Time frame: Week 24, Week 36 and Week 52

  16. Change from Baseline in Quality of Life Assessment Score at Weeks 24, 36 and 52

    Time frame: Baseline, Week 24, Week 36 and Week 52

  17. Number of Participants Achieving Reduction from Baseline in Quality of Life Assessment Score at Weeks 24, 36 and 52 in Participants with Baseline Score Greater Than or Equal to a Cutoff Score

    Time frame: Baseline, Week 24, Week 36 and Week 52

  18. Change from Baseline in Weekly Average of Daily Skin Pain Assessment Score at Weeks 24, 36 and 52

    Time frame: Baseline, Week 24, Week 36 and Week 52

  19. Change from Baseline in Weekly Average of Daily Sleep Disturbance Assessment Score at Weeks 24, 36 and 52

    Time frame: Baseline, Week 24, Week 36 and Week 52

  20. Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Sleep Disturbance Assessment Score at Weeks 24, 36 and 52 in Participants with Baseline Weekly Average Score Greater Than or Equal to a Cutoff Score

    Time frame: Baseline, Week 24, Week 36 and Week 52

  21. Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 36 and 52

    Time frame: Baseline, Week 36 and Week 52

  22. Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Skin Pain Assessment Score at Week 36 and 52 in Participants With Baseline Score Greater Than or Equal to a Cutoff Score

    Time frame: Baseline, Week 36 and Week 52

07

Study locations

192 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Los Angeles Universal Research Center
    Los Angeles, California 90057, United States
  • Paradigm Clinical Research Center Inc
    San Diego, California 92108, United States
  • Wolverine Clinical Trials
    Santa Ana, California 92706, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Southern Clinical Research
    Miami, Florida 33125, United States
  • University of Miami Hospital
    Miami, Florida 33125, United States
  • Miami Dermatology and Laser Institute
    Miami, Florida 33173, United States
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
  • Clinical Research Trials of Florida Inc
    Tampa, Florida 33607, United States
  • Olympian Clinical Research - Tampa
    Tampa, Florida 33615, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Endeavor Health Clinical Trials Center
    Skokie, Illinois 60077, United States
  • The Indiana Clinical Trials Center PC
    Plainfield, Indiana 46168, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10028, United States
  • Optima Research
    Boardman, Ohio 44512, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Wright State Physicians
    Fairborn, Ohio 45324, United States
  • Hightower Clinical
    Oklahoma City, Oklahoma 73102, United States
  • Center For Clinical Studies PLLC
    Houston, Texas 77004, United States
  • Clarity Dermatology
    Lancaster, Texas 75146, United States
  • Springville Dermatology
    Springville, Utah 84663, United States
  • Hospital Universitario Austral
    Derqui, Pilar, Buenos Aires B1629ODT, Argentina
  • Instituto de Investigaciones Clinicas de Cordoba
    Córdoba, Córdoba Province X5000AAW, Argentina
  • Instituto de Neumonologia y Dermatologia
    Buenos Aires, Distrito Federal 1425, Argentina
  • Derma Internacional
    Buenos Aires, Distrito Federal C1426EGR, Argentina
  • Centro de investigacion clinica y epidemiologica
    San Miguel D Tucuman, Tucumán Province T4000DPL, Argentina
  • Parra Dermatologia
    Mendoza, M5500AWD, Argentina
  • St George Dermatology and Skin Cancer Centre
    Kogarah, New South Wales 2217, Australia
  • Veracity Clinical Research
    Woolloongabba, Queensland 4102, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Medizinische Universitaet Graz
    Graz, 8036, Austria
  • Ordensklinikum Linz Elisabethinen
    Linz, 4020, Austria
  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Universitaire Ziekenhuizen Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege - Sart Tilman
    Liège, 4000, Belgium
  • Clinica Instituto Bahiano de Imunoterapia - Medicina, Reumatologia e Dermatologia ltda
    Salvador, Estado de Bahia 41820-020, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Universidade Estadual Paulista Julio de Mesquita Filho
    Botucatu, São Paulo 18618-686, Brazil
  • Fundacao Abc - Centro Univ Fmabc
    Santo André, São Paulo 09060-870, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, São Paulo 05403-002, Brazil
  • IBPClin Instituto Brasil de Pesquisa Clinica
    Rio de Janeiro, 20241-180, Brazil
  • Doctor Chih-Ho Hong Medical Incorporated
    Surrey, British Columbia V3R 6A7, Canada
  • Skincare Studio
    St. John's, Newfoundland and Labrador A1E 1V4, Canada
  • CCA Medical Research Corp
    Ajax, Ontario L1S 7K8, Canada
  • Centricity Research London Victoria
    London, Ontario N6A 2C2, Canada
  • Lovegrove Dermatology
    London, Ontario N6A 5R9, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X3, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • York Dermatology Clinic and Research Centre
    Richmond Hill, Ontario L4B 1L1, Canada
  • Toronto Research Centre Inc
    Toronto, Ontario M3H 5Y8, Canada
  • AvantDerm
    Toronto, Ontario M5A 3R6, Canada
  • Alliance Clinical Trials
    Waterloo, Ontario N2J 1C4, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitain
    Québec, Quebec G1V 4X7, Canada
  • Enroll SpA
    Providencia, Santiago Metropolitan 7500587, Chile
  • Centro Medico Skinmed Spa
    Santiago, 7580206, Chile
  • Fundacion Innovacion Cardiovascular Clinica Ensenada
    Santiago, 8380465, Chile
  • Centro Internacional de Estudios Clinicos
    Santiago, Chile
  • Clinical Research Chile SpA
    Valdivia, 5110683, Chile
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • The First Affiliated Hospital Sun-Yat Sen University
    Guangzhou, Guangdong 510080, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
  • Nanfang Hospital Southern Medical University
    Guangzhou, Guangdong 510515, China
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Sanmenxia Central Hospital
    Sanmenxia, Henan 472099, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Wuxi Peoples Hospital
    Wuxi, Jiangsu 214043, China
  • Dermatology Hospital of Jiangxi Province
    Nanchang, Jiangxi 330000, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The Second Affiliated Hospital Of Xi An Jiaotong University
    Xi'an, Shaanxi 71004, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200443, China
  • Chengdu Second Peoples Hospital
    Chengdu, Sichuan 610017, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • The Second Affliated Hospital of Kunming Medical University
    Kunming, Yunnan 650101, China
  • Affiliated Hangzhou First Peoples Hospital School of Medicine Westlake University
    Hangzhou, Zhejiang 310020, China
  • Clinical Research Services Helsinki
    Helsinki, 00180, Finland
  • Oulun Yliopistollinen sairaala
    Oulu, 90029, Finland
  • Terveystalo Tampere
    Tampere, 33100, Finland
  • Centre Hospitalier Regional Universitaire de Brest - Hopital Morvan
    Brest, 29200, France
  • Centre Hospitalier Le Mans
    Le Mans, 72037, France
  • Cabinet du Docteur Ruer-Mulard Mireille
    Martigues, 13500, France
  • Centre Hospitalier Universitaire Archet 2
    Nice, 06202, France
  • Centre Hospitalier Universitaire de Rouen - Hopital Charles Nicolle
    Rouen, 76031, France
  • Universitaetsklinikum Augsburg
    Augsburg, 86156, Germany
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Charite - Universitaetsmedizin Berlin, Campus Virchow
    Berlin, 12203, Germany
  • Rosenpark Research GmbH
    Darmstadt, 64283, Germany
  • Universitaetsklinikum Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Schleswig-Holstein - Kiel
    Kiel, 24105, Germany
  • Universitaetsmedizin Mainz
    Mainz, 55101, Germany
  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
  • Hautarztpraxis Mortazawi
    Remscheid, 42897, Germany

Showing the first 100 of 192 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Apr 2026, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Jul 30, 2024
StartActual
Jul 18, 2024
Primary completionActual
Apr 17, 2026
CompletionActual
Jun 25, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06527404
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Jul 18, 2024
Primary completion
Apr 17, 2026
Completion
Jun 25, 2026
Last update
Jul 27, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KHK4083

Start the discussion